Moderna Inc. ($MRNA) Stock Forecast: Down 5.2% Today

What is Moderna Inc.?

Moderna, Inc. (MRNA) is a biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines.

Why is Moderna Inc. going down?

MRNA stock is down 5.2% on May 28, 2026 13:42

• The bearish movement in Moderna's stock today can be attributed to:
• Perceived overbought conditions and technical indicators signaling reversals, leading traders to take short positions.
• Concerns about the stock being fundamentally overvalued, especially after its recent inclusion in the S&P 500 index.
• Lack of significant positive news catalysts to sustain the recent bullish momentum.
• Despite the bearish movement, the upcoming FDA advisory committee review for Moderna's mRNA flu shot and the company's preparations for a COVID-19 booster vaccine targeting the XFG strain in 2026–27 could potentially drive positive sentiment and future price movements.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna, Inc. Trade Ideas — LS:A2N9D9 — TradingView

This article compiles various trading ideas for Moderna, Inc. (A2N9D9/MRNA) from multiple traders on TradingView. The ideas predominantly suggest short positions due to perceived overbought conditions, technical indicators signaling reversals, and the stock being fundamentally overvalued, especially after its S&P 500 inclusion. Some traders also present long positions based on Delta variant news, technological advantages of mRNA, and bullish chart patterns.

https://www.tradingview.com/symbols/LS-A2N9D9/ideas/page-28/

YieldMax MRNA option income strategy ETF announces weekly distribution of $0.2357

The YieldMax MRNA option income strategy ETF has declared a weekly distribution of $0.2357 per share. This announcement provides current income details for investors holding the MRNA-focused ETF.

http://www.msn.com/en-us/health/other/yieldmax-mrna-option-income-strategy-etf-announces-weekly-distribution-of-0-2357/ar-AA24btPq?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

Eli Lilly has expanded aggressively, notably acquiring three vaccine companies and reaching new benchmarks in weight loss with retatrutide and advancing a cholesterol-lowering gene therapy. Moderna's stock saw an unexpected rise attributed to hantavirus fears, and its mRNA flu shot is scheduled for an FDA advisory committee review. The article also highlights upcoming excitement at the American Society of Clinical Oncology (ASCO) conference, with focus on Revolution Medicines' pancreatic cancer pill and Akeso's bispecific ivonescimab.

https://www.biospace.com/deals/lilly-wheels-and-deals-moderna-gets-boost-on-hantavirus-scare-asco-excitement-builds

Key facts: Moderna Readies 2026–27 XFG Booster; FDA Advisers to Vote

Moderna (MRNA) is preparing a COVID-19 booster vaccine for the 2026–27 season, targeting the dominant XFG strain. FDA advisers are scheduled to vote on updating the vaccine composition to address this new strain. This move follows discussions between regulators and vaccine manufacturers regarding the necessary updates.

https://www.tradingview.com/news/tradingview:763eaa865b419:0-key-facts-moderna-readies-2026-27-xfg-booster-fda-advisers-to-vote/

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

Neurocrine Biosciences announced that its executives will participate in two investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Webcasts of these fireside chats will be available on the company’s website. Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders.

https://finance.yahoo.com/sectors/healthcare/articles/neurocrine-biosciences-present-upcoming-investor-200100170.html

Trending Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Up 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 8.7% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.3% Today

Autodesk Inc. ($ADSK) Stock Forecast: Down 5.0% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 14.8% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 12.4% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Up 0.6% Today

Capri Holdings Limited ($CPRI) Stock Forecast: Down 5.6% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.2% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.4% Today

Moderna Inc. Price History

12.04.2026 - MRNA Stock was down 6.7%

• Moderna (MRNA) faced a downturn today, potentially influenced by profit-taking following recent positive developments.
• The dip in Merck's stock value, attributed to a one-time charge stemming from an acquisition and a setback in its pipeline, may have impacted overall sentiments towards biotech equities, including Moderna.
• Investor attention could have shifted towards companies like Halozyme Therapeutics (HALO) with optimistic revenue projections, prompting a brief sell-off in Moderna shares.
• Market influencers within the biotech domain embracing cutting-edge technologies such as AI might have diverted focus away from Moderna, contributing to its bearish performance today.

28.04.2026 - MRNA Stock was down 5.2%

• The bearish movement in Moderna's stock today can be attributed to:
• Perceived overbought conditions and technical indicators signaling reversals, leading traders to take short positions.
• Concerns about the stock being fundamentally overvalued, especially after its recent inclusion in the S&P 500 index.
• Lack of significant positive news catalysts to sustain the recent bullish momentum.
• Despite the bearish movement, the upcoming FDA advisory committee review for Moderna's mRNA flu shot and the company's preparations for a COVID-19 booster vaccine targeting the XFG strain in 2026–27 could potentially drive positive sentiment and future price movements.

08.04.2026 - MRNA Stock was up 13.7%

• Moderna's bullish movement can be attributed to the positive Phase 3 flu vaccine data for its mRNA-1010 candidate, showcasing superior efficacy compared to standard flu vaccines.
• The SEC filing indicating a proposed sale of securities might have initially caused some uncertainty but was overshadowed by the promising vaccine results.
• The positive news from Regeneron Pharmaceuticals receiving FDA approval for the first neurosensory gene therapy could have boosted overall investor sentiment in the biotech sector, benefiting Moderna as well.
• Moderna's potential for building durable revenue beyond COVID-19 vaccines with upcoming FDA approvals could have further fueled investor optimism, driving the stock's bullish momentum.

08.04.2026 - MRNA Stock was up 11.8%

• Ongoing research into hantavirus vaccines by Moderna may have boosted investor confidence in the company's ability to address emerging infectious diseases, contributing to the bullish movement.
• A SEC filing indicating a proposed sale of securities by Moderna may have initially caused some uncertainty among investors, but the overall positive sentiment surrounding the company's vaccine development efforts likely overshadowed this news.
• The broader positive sentiment in the biotechnology sector, as evidenced by Cboe Global Markets hitting an all-time high, could have also positively influenced Moderna's stock performance today.
• Moderna's focus on advancing its vaccine pipeline, as seen in the update on its RSV and H5 flu vaccine trial, may have further reinforced investor optimism in the company's long-term growth prospects, contributing to the bullish market movement.

11.04.2026 - MRNA Stock was down 7.7%

• Despite a 6% surge earlier, Moderna's stock faced a bearish movement, potentially influenced by profit-taking following recent positive momentum.
• Initially boosted by renewed interest in Moderna's Hantavirus vaccine due to an outbreak, concerns about normalizing COVID-era revenue and GAAP losses may have contributed to the downturn.
• Investors seem to exercise caution due to uncertainties surrounding the revenue potential of the broader mRNA platform and the company's ability to sustain competitiveness against peers like Pfizer and Novavax in the vaccine sector.
• While the market sentiment towards Moderna remains positive, driven by upcoming Phase 3 readouts and a diverse pipeline, short-term volatility could linger as investors navigate challenges tied to the pandemic.

11.04.2026 - MRNA Stock was down 5.1%

• Moderna's stock increased by 6% today, surpassing other vaccine companies like Pfizer and Novavax. This was driven by heightened interest in its Hantavirus vaccine after a recent outbreak on a cruise ship and robust Q1 2026 revenue results. However, concerns about returning to pre-COVID revenue levels and ongoing losses might have led to profit-taking and a bearish trend in the stock.
• Moderna's wide-ranging mRNA platform, along with upcoming Phase 3 study outcomes, continues to support its positive market momentum despite the recent decline.
• The overall market sentiment towards biotech companies and uncertainties about future revenue sustainability post-COVID may have played a role in today's downward movement for Moderna's stock.
• Investors are likely approaching Moderna's stock with caution due to uncertainties surrounding its revenue sources and future profitability.

20.04.2026 - MRNA Stock was up 5.1%

• Moderna's stock surged by 20% due to emerging hantavirus cases, showcasing the market's confidence in the company's pandemic defense capabilities.
• The hantavirus scare not only boosted Moderna's stock but also highlighted the potential changes in vaccine-related regulatory environments, which could further benefit the company.
• Despite concerns about declining sales and profitability, Moderna's focus on infectious disease platforms and potential vaccine developments seems to have overshadowed these worries, driving the bullish movement in its stock today.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement despite being ranked #1 on a list of Most Impactful Companies, showcasing its significant contributions to mRNA technology and public health.
• The company's Q1 earnings report with an EPS of ($3.40) may have contributed to the drop in share price, signaling potential investor concerns about profitability.
• Investors viewing Moderna as a pandemic hedge amidst reduced demand for Covid vaccines and regulatory challenges might have led to conflicting sentiments and added to the stock's volatility.
• The overall market sentiment towards biotech companies and vaccine manufacturers could have influenced Moderna's stock movement, with investors closely monitoring developments in the healthcare sector.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna observed a downward trend in its stock price today despite investor confidence in its pandemic-related value. Possible reasons for this decline include:
• Decreased demand for Covid vaccines and regulatory challenges impacting investor optimism.
• Moderna faces uncertainties regarding its future trajectory and the viability of potential trading strategies related to the "hantavirus."
• News of Dominari Holdings' strong Q1 revenue growth and Sinovac Foundation's vaccine donations might have shifted investor focus away from Moderna, affecting its stock performance.
• Denison Mines' underwhelming earnings results and a poor financial health rating from InvestingPro could have contributed to negative overall market sentiment in the healthcare and biotech sectors, influencing Moderna's stock performance.

13.04.2026 - MRNA Stock was down 5.4%

• The stock of Moderna faced a downturn despite being acknowledged as a highly impactful company globally.
• Factors such as declining demand for COVID vaccines and a complex regulatory environment may have influenced the market's pessimistic view.
• Investors appear wary of Moderna's future trajectory, particularly as the company navigates critical decisions and places bets on a "hantavirus trade" to regain momentum.
• While Moderna has received acclaim for its mRNA technology innovations, current market sentiment seems more concerned with the company's present obstacles and uncertainties.

19.04.2026 - MRNA Stock was down 5.1%

• Moderna's bearish movement today may be linked to an insider sale by President Stephen Hoge, potentially unsettling investors and adding to stock volatility.
• The market sentiment around mRNA technology and the company's need to stabilize revenue post-pandemic could be contributing to the downward trend, despite positive growth from international partnerships and new vaccines.
• Investors may also be reacting to potential legal risks from intellectual property disputes, as mentioned in a recent conference audio transcript, which might be impacting Moderna's stock performance.
• The company's strong clinical and regulatory progress, beneficial for its long-term prospects, may not be sufficient to counter the immediate market factors influencing today's bearish movement.

19.04.2026 - MRNA Stock was down 6.9%

• Moderna's stock faced a downward trend subsequent to an insider selling 53,336 shares, conducted by President Stephen Hoge. This transaction heightened stock volatility, indicating investor sensitivity to internal activities.
• The market's adverse response to the insider sale potentially reflects uncertainties about Moderna's future growth trajectory and stability post-pandemic.
• Investor focus remains on Moderna's vaccine demand, progress in pipeline projects, and endeavors to stabilize revenue, all pivotal in determining stock performance.
• Noteworthy advancements from Wave Life Sciences regarding its AATD trial possibly impacted the biotech sector positively, while Moderna's descent was influenced by the insider transaction.